A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
A Phase III, 12-Week, Multicentre, Double-Blind, Randomised, Placebo- and Active Comparator-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of GW406381, 5mg, 10mg, 25mg, and 50mg Administered Orally Once Daily, in Adults With Rheumatoid Arthritis
This study is being conducted to find out if an investigational drug called GW406381 can help people with rheumatoid arthritis.
Inclusion criteria:
Exclusion criteria:
Gainsville, Georgia 30501, United States
Concinnati, Ohio 45219, United States
Mayfield Village, Ohio 44143, United States
Muckleneuk, Gauteng 0001, South Africa
Erasmus Kloof, Pretoria, 0048, South Africa
Baracaldo/Vizcaya, 48903, Spain